Rapid Molecular Diagnostic Platform Sends Precise COVID-19 RNA Results to Smartphone in Minutes

An all new technology can detect COVID-19 RNA in saliva through newly developed electronic nanosensors, which significantly reduces error rates associated with chemical-based home tests.

IdentifySensors Biologics (Cleveland, OH, USA), a nanosensor technology firm which has developed the rapid diagnostic platform for detecting pathogens, including SARS-CoV-2, has now joined the SMART Film Consortium, led by the Birck Nanotechnology Center at Purdue University (West Lafayette, IN, USA) that seeks to develop the first foundry dedicated to low-cost non-silicon printed sensors.


Unlike other molecular tests for COVID-19, the rapid molecular diagnostic platform automatically transmits test results to consumer smartphones and to the proper health agencies in minutes. The platform technology can be easily modified to also detect influenza, Zika, dengue, HIV/AIDS, hepatitis C, Lyme disease, mumps, measles, chickenpox and methicillin-resistant staphylococcus Aureus (MRSA) and foodborne pathogens.

"By joining the SMART Film Consortium, IdentifySensors Biologics has positioned itself in a significantly strategic vantage point where it is able to tap into a wide array of printing and scalable manufacturing resources in the Birck Nanotechnology Center to greatly accelerate the development of their COVID-19 sensor," said Thomas Sors, assistant director of the Purdue Institute of Inflammation, Immunology and Infectious Disease.

Related Links:
IdentifySensors Biologics
Purdue Research Foundation